Clioquinol / Hydrocortisone Topical Dosage

Usual Adult Dose for Dermatitis

Apply a thin layer to the affected area 3 to 4 times a day.

Usual Adult Dose for Eczema

Apply a thin layer to the affected area 3 to 4 times a day.

Usual Adult Dose for Pruritus

Apply a thin layer to the affected area 3 to 4 times a day.

Usual Pediatric Dose for Dermatitis

Less than 2 years: Use is not recommended.
2 years or older: Apply a thin layer to the affected area 3 to 4 times a day.

Usual Pediatric Dose for Eczema

Less than 2 years: Use is not recommended.
2 years or older: Apply a thin layer to the affected area 3 to 4 times a day.

Usual Pediatric Dose for Pruritus

Less than 2 years: Use is not recommended.
2 years or older: Apply a thin layer to the affected area 3 to 4 times a day.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Consult WARNINGS section for dosing related precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-For external use only; do not use in or around the eyes.

Storage requirements:
-Should be stored at room temperature 15C to 30C (59F to 86F) in original container; should protect from freezing

General:
-Occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.
-This drug not found safe and effective by FDA; the manufacturer's product labeling has not been approved by FDA.
-Based on a review by the National Academy of Sciences-National Research Council and/or other information, this drug has been classified by the FDA as "possibly" effective for the following indications: contact or atopic dermatitis, impetiginized eczema, nummular eczema, infantile eczema, endogenous chronic infectious dermatitis, stasis dermatitis, pyoderma, nuchal eczema and chronic eczematoid otitis externa, acne urticata, localized or disseminated neurodermatitis, lichen simplex chronicus, anogenital pruritus (vulvae, scroti, ani), folliculitis, bacterial dermatoses, mycotic dermatoses (such as tinea [capitis, cruris, corporis, pedis]), moniliasis, intertrigo.
-Final classification of less-than-effective indications requires further investigation.

Monitoring:
-Endocrine: Urinary free cortisol and ACTH stimulation tests